Lung Neoplasms: Tumors or cancer of the LUNG.Tetranitromethane: Corrosive oxidant, explosive; additive to diesel and rocket fuels; causes skin and lung irritation; proposed war gas. A useful reagent for studying the modification of specific amino acids, particularly tyrosine residues in proteins. Has also been used for studying carbanion formation and for detecting the presence of double bonds in organic compounds.Chloroprene: Toxic, possibly carcinogenic, monomer of neoprene, a synthetic rubber; causes damage to skin, lungs, CNS, kidneys, liver, blood cells and fetuses. Synonym: 2-chlorobutadiene.Flame Retardants: Materials applied to fabrics, bedding, furniture, plastics, etc. to retard their burning; many may leach out and cause allergies or other harm.Adenocarcinoma, Bronchiolo-Alveolar: A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)Propylene Glycols: Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations.Lung: Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.Genes, ras: Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.Mice, Inbred Strains: Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.Codon: A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE).Lung Diseases: Pathological processes involving any part of the LUNG.Lung Injury: Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Lung Transplantation: The transference of either one or both of the lungs from one human or animal to another.Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.Acute Lung Injury: A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).Skin Neoplasms: Tumors or cancer of the SKIN.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Lung Volume Measurements: Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.DNA, Neoplasm: DNA present in neoplastic tissue.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Liver Neoplasms: Tumors or cancer of the LIVER.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Neoplasms, Connective and Soft Tissue: Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.Neoplasms, Plasma Cell: Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.Appendiceal Neoplasms: Tumors or cancer of the APPENDIX.Total Lung Capacity: The volume of air contained in the lungs at the end of a maximal inspiration. It is the equivalent to each of the following sums: VITAL CAPACITY plus RESIDUAL VOLUME; INSPIRATORY CAPACITY plus FUNCTIONAL RESIDUAL CAPACITY; TIDAL VOLUME plus INSPIRATORY RESERVE VOLUME plus functional residual capacity; or tidal volume plus inspiratory reserve volume plus EXPIRATORY RESERVE VOLUME plus residual volume.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Pulmonary Alveoli: Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place.Extravascular Lung Water: Water content outside of the lung vasculature. About 80% of a normal lung is made up of water, including intracellular, interstitial, and blood water. Failure to maintain the normal homeostatic fluid exchange between the vascular space and the interstitium of the lungs can result in PULMONARY EDEMA and flooding of the alveolar space.Cystadenoma, Mucinous: A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Neoplasms, Radiation-Induced: Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Endocrine Gland Neoplasms: Tumors or cancer of the ENDOCRINE GLANDS.Bronchoalveolar Lavage Fluid: Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung.Nose Neoplasms: Tumors or cancer of the NOSE.Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Small Cell Lung Carcinoma: A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Adenoma: A benign epithelial tumor with a glandular organization.Eye Neoplasms: Tumors or cancer of the EYE.Neoplasms, Vascular Tissue: Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Neoplasms, Muscle Tissue: Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Uterine Neoplasms: Tumors or cancer of the UTERUS.Lung Abscess: Solitary or multiple collections of PUS within the lung parenchyma as a result of infection by bacteria, protozoa, or other agents.Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Intestinal Neoplasms: Tumors or cancer of the INTESTINES.Vascular Neoplasms: Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.Neoplasms, Adnexal and Skin Appendage: Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.Ventilator-Induced Lung Injury: Lung damage that is caused by the adverse effects of PULMONARY VENTILATOR usage. The high frequency and tidal volumes produced by a mechanical ventilator can cause alveolar disruption and PULMONARY EDEMA.Neoplasms, Complex and Mixed: Neoplasms composed of more than one type of neoplastic tissue.Sweat Gland NeoplasmsColonic Neoplasms: Tumors or cancer of the COLON.Palatal Neoplasms: Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Mandibular Neoplasms: Tumors or cancer of the MANDIBLE.Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.Splenic Neoplasms: Tumors or cancer of the SPLEEN.Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Heart Neoplasms: Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Dog Diseases: Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.Respiratory Function Tests: Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Cystadenoma, Serous: A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)Pneumonia: Infection of the lung often accompanied by inflammation.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Maxillary Neoplasms: Cancer or tumors of the MAXILLA or upper jaw.Mice, Inbred C57BLPneumonectomy: The excision of lung tissue including partial or total lung lobectomy.Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.Neoplasms, Germ Cell and Embryonal: Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.Anal Gland Neoplasms: Tumors or cancer of the anal gland.Pleural Neoplasms: Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Mediastinal Neoplasms: Tumors or cancer of the MEDIASTINUM.Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.Pulmonary Edema: Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.Neoplasms, Adipose Tissue: Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Farmer's Lung: A form of alveolitis or pneumonitis due to an acquired hypersensitivity to inhaled antigens associated with farm environment. Antigens in the farm dust are commonly from bacteria actinomycetes (SACCHAROPOLYSPORA and THERMOACTINOMYCES), fungi, and animal proteins in the soil, straw, crops, pelts, serum, and excreta.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Duodenal Neoplasms: Tumors or cancer of the DUODENUM.Cell Line, Tumor: A cell line derived from cultured tumor cells.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Smoking: Inhaling and exhaling the smoke of burning TOBACCO.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Mouth Neoplasms: Tumors or cancer of the MOUTH.Carcinogens: Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.Respiratory Distress Syndrome, Adult: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.Stomach Neoplasms: Tumors or cancer of the STOMACH.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Breast Neoplasms: Tumors or cancer of the human BREAST.Adrenal Cortex Neoplasms: Tumors or cancers of the ADRENAL CORTEX.Pulmonary Circulation: The circulation of the BLOOD through the LUNGS.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Tongue Neoplasms: Tumors or cancer of the TONGUE.Muscle Neoplasms: Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.Hemangiosarcoma: A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)Ileal Neoplasms: Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).Carcinoma, Acinar Cell: A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)Liver Neoplasms, Experimental: Experimentally induced tumors of the LIVER.Nervous System Neoplasms: Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.Spinal Cord Neoplasms: Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.Bronchi: The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.Pulmonary Emphysema: Enlargement of air spaces distal to the TERMINAL BRONCHIOLES where gas-exchange normally takes place. This is usually due to destruction of the alveolar wall. Pulmonary emphysema can be classified by the location and distribution of the lesions.Vaginal Neoplasms: Tumors or cancer of the VAGINA.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Pulmonary Surfactants: Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI.Adenoma, Oxyphilic: A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.Janus Kinase 2: A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.Respiratory Mucosa: The mucous membrane lining the RESPIRATORY TRACT, including the NASAL CAVITY; the LARYNX; the TRACHEA; and the BRONCHI tree. The respiratory mucosa consists of various types of epithelial cells ranging from ciliated columnar to simple squamous, mucous GOBLET CELLS, and glands containing both mucous and serous cells.Myelodysplastic-Myeloproliferative Diseases: Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.Paranasal Sinus Neoplasms: Tumors or cancer of the PARANASAL SINUSES.Pancreatectomy: Surgical removal of the pancreas. (Dorland, 28th ed)Cerebral Ventricle Neoplasms: Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.Abdominal NeoplasmsPeripheral Nervous System Neoplasms: Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.

Human papillomavirus DNA in adenosquamous carcinoma of the lung. (1/26018)

AIM: To investigate the presence of human papillomavirus (HPV) DNA in adenosquamous carcinoma of the lung--which is relatively common in Okinawa but not in mainland Japan--and examine its histological features. METHODS: Of 207 cases where primary lung cancers were surgically removed between January 1995 and June 1997 in Okinawa, 23 were adenosquamous carcinoma. HPV was detected by non-isotopic in situ hybridisation (NISH) and polymerase chain reaction (PCR) amplification with primers specific for E6 and E7 regions of the HPV genome. PCR products were analysed by Southern blotting. Immunohistochemical determination of high molecular weight cytokeratin (HMC) and involucrin was also carried out. RESULTS: 18 cases were positive for HPV DNA by PCR and NISH. HPV types 6, 11, 16, and 18 were found. Seven cases were dual positive for different types of HPV. Using NISH, HPV was also found in the squamous cell components and in neighbouring enlarged adenocarcinoma cells. The HMC and involucrin were demonstrated immunohistochemically in the same areas. CONCLUSIONS: HPV DNA was found in a high proportion (78.3%) of adenosquamous carcinomas in Okinawa, a region where HPV has previously been shown to be prevalent in squamous cell carcinoma of the lung. The adenocarcinoma cells adjacent to the squamous cell carcinoma component were enlarged and positive for HPV, HMC, and involucrin. This is thought to indicate the transition from adenocarcinoma to squamous cell carcinoma.  (+info)

Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. (2/26018)

The association of p53 abnormalities with the prognosis of patients with non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial. Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC. p53 mutations were detected in 49 of 103 (48%) tumors. Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8. Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression was only 69%. p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P<0.001). Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P=0.243 in null mutations). These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.  (+info)

Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. (3/26018)

OBJECTIVE: To determine the sensitivity, specificity, and accuracy of positron emission tomography with 2-fluorine-18-fluorodeoxyglucose (PET-FDG) in the preoperative staging (N and M staging) of patients with lung cancer. The authors wanted to compare the efficacy of PET scanning with currently used computed tomography (CT) scanning. MATERIALS AND METHODS: Results of whole-body PET-FDG imaging and CT scans were compared with histologic findings for the presence or absence of lymph node disease or metastatic sites. Sampling of mediastinal lymph nodes was performed using mediastinoscopy or thoracotomy. RESULTS: PET-FDG imaging was significantly more sensitive, specific, and accurate for detecting N disease than CT. PET changed N staging in 35% and M staging in 11% of patients. CT scans helped in accurate anatomic localization of 6/57 PET lymph node abnormalities. CONCLUSION: PET-FDG is a reliable method for preoperative staging of patients with lung cancer and would help to optimize management of these patients. Accurate lymph node staging of lung cancer may be ideally performed by simultaneous review of PET and CT scans.  (+info)

Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. (4/26018)

Cellular and molecular mechanisms involved in the resistance to cytotoxic heavy metals remain largely to be characterized in mammalian cells. To this end, we have analyzed a metal-resistant variant of the human lung cancer GLC4 cell line that we have selected by a step-wise procedure in potassium antimony tartrate. Antimony-selected cells, termed GLC4/Sb30 cells, poorly accumulated antimony through an enhanced cellular efflux of metal, thus suggesting up-regulation of a membrane export system in these cells. Indeed, GLC4/Sb30 cells were found to display a functional overexpression of the multidrug resistance-associated protein MRP1, a drug export pump, as demonstrated by Western blotting, reverse transcriptase-polymerase chain reaction and calcein accumulation assays. Moreover, MK571, a potent inhibitor of MRP1 activity, was found to markedly down-modulate resistance of GLC4/Sb30 cells to antimony and to decrease cellular export of the metal. Taken together, our data support the conclusion that overexpression of functional MRP1 likely represents one major mechanism by which human cells can escape the cytotoxic effects of heavy metals.  (+info)

Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. (5/26018)

Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3+/-23.5 ng 10(-6) cells, mean +/- s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2+/-0.1 ng 10(-6) cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.  (+info)

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. (6/26018)

Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification.  (+info)

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. (7/26018)

The assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention.  (+info)

Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. (8/26018)

Three different membrane-type matrix metalloproteinases (MT1-, MT2-, and MT3-MMPs) are known to activate in vitro the zymogen of MMP-2 (pro-MMP-2, progelatinase A), which is one of the key MMPs in invasion and metastasis of various cancers. In the present study, we have examined production and activation of pro-MMP-2, expression of MT1-, MT2-, and MT3-MMPs and their correlation with pro-MMP-2 activation, and localization of MMP-2, MT1-MMP, and MT2-MMP in human astrocytic tumors. The sandwich enzyme immunoassay demonstrates that the production levels of pro-MMP-2 in the anaplastic astrocytomas and glioblastomas are significantly higher than that in the low-grade astrocytomas (P<0.05 and P<0.01, respectively), metastatic brain tumors (P<0.05), or normal brains (P<0.01). Gelatin zymography indicates that the pro-MMP-2 activation ratio is significantly higher in the glioblastomas than in other astrocytic tumors (P<0.01), metastatic brain tumors (P<0.01), and normal brains (P<0.01). The quantitative reverse transcription polymerase chain reaction analyses demonstrate that MT1-MMP and MT2-MMP are expressed predominantly in glioblastoma tissues (17/17 and 12/17 cases, respectively), and their expression levels increase significantly as tumor grade increases. MT3-MMP is detectable in both astrocytic tumor and normal brain tissues, but the mean expression level is approximately 50-fold lower compared with that of MT1-MMP and MT2-MMP in the glioblastomas. The activation ratio of pro-MMP-2 correlates directly with the expression levels of MT1-MMP and MT2-MMP but not MT3-MMP. In situ hybridization indicates that neoplastic astrocytes express MT1-MMP and MT2-MMP in the glioblastoma tissues (5/5 cases and 5/5 cases, respectively). Immunohistochemically, MT1-MMP and MT2-MMP are localized to the neoplastic astrocytes in glioblastoma samples (17/17 cases and 12/17 cases, respectively), which are also positive for MMP-2. In situ zymography shows gelatinolytic activity in the glioblastoma tissues but not in the normal brain tissues. These results suggest that both MT1-MMP and MT2-MMP play a key role in the activation of pro-MMP-2 in the human malignant astrocytic tumors and that the gelatinolytic activity is involved in the astrocytic tumor invasion.  (+info)

Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021 Conference call and webcast today at 5:00 p.m. ET to review third quarter 2019 Financial results and the new nasal swab test data Veracyte, Inc. (Nasdaq: VCYT) today announced preliminary clinical data showing that the companys noninvasive nasal swab test - the first of its kind - can enable early lung cancer detection and diagnosis so that more lives can be saved. The new findings specifically show that the novel genomic test can accurately classify lung cancer risk in patients with lung nodules so that these patients can obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively. The findings will be presented today at the annual meeting of the American College of Chest Physicians® (CHEST) in New Orleans. "Early ...
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? Lung cancer;neutrophil to lymphocyte ratio;prognostic factors;C reactive protein; Background: Although many prognostic factors have been identified for lung cancers, new ones are needed to determine the course of the disease. Recently, a high neutrophil to lymphocyte ratio (NLR) prior to surgery or treatment has been shown to be an indicator of prognosis for cancer. The aim of this study was to investigate the value of NLR as a prognostic factor and the correlation between NLR and other probable clinical prognostic factors in non small cell lung cancer patients prior to treatment. Materials and Methods: Data of patients who were diagnosed with non-small cell lung cancer in our institution were retrospectively reviewed. Demographic and clinicopathologic characteristics were recorded. NLR was calculated before the application of any treatment. Results: A total of 299 patients, 270 (90%) males and 29 (10
Since this squamous cell lung cancer is being considered as destructive neoplasm in lungs, additional care is paid towards incorporating the effective supportive therapy in the regular anti cancerous therapy, involving multi drug combinations. The supportive therapy may include usage of suitable corticosteroid drugs like prednisolone in a routine form and it is noteworthy to mention that in some patients, a repository form of this corticosteroid may also be used to fulfill the need of constant delivery.. Surgery is also being considered as therapy in cases of squamous cell lung cancer. But, if the spread of this is over a wide area, it becomes impossible.. The squamous cell lung cancer in many patients tends to spread to other tissues including kidney or bone. Suppose, if it spreads to bones, most of the times, mandible or skull may get affected and in such cases increased density with occurrence of periosteal new bones may be noticed.. Squamous cell lung cancer at times need confirmation from ...
Non‑small cell lung cancer (NSCLC) constitutes the majority of all lung‑cancer cases. Aquaporin 5 (AQP5) may be involved in NSCLC by promoting lung‑cancer initiation and progression. The present study aimed to determine the role of AQP5 in migration and angiogenesis using NSCLC cells and HUVECs. AQPs 1, 3, 4, 5, 8 and 9 were screened in the NSCLC cell line H1299, and the present results showed that AQP5 mRNA was upregulated compared with the other AQP genes. At the protein level, AQP5 was significantly increased in H1299 cells compared with 16HBE cells. AQP5 knockdown in H1299 cells significantly decreased cell migration compared with untransfected cells, as demonstrated by both Transwell and wound closure assays. The present study further investigated H1299 ability to promote HUVEC vascularisation. The supernatants of both transfected and untransfected H1299 cells were used as conditioned medium for HUVECs, and tube formation was measured. The supernatant of AQP5‑downregulated cells ...
TY - JOUR. T1 - Mutational analysis of multiple lung cancers. T2 - Discrimination between primary and metastatic lung cancers by genomic profile. AU - Goto, Taichiro. AU - Hirotsu, Yosuke. AU - Mochizuki, Hitoshi. AU - Nakagomi, Takahiro. AU - Shikata, Daichi. AU - Yokoyama, Yujiro. AU - Oyama, Toshio. AU - Amemiya, Kenji. AU - Okimoto, Kenichiro. AU - Omata, Masao. PY - 2017/1/1. Y1 - 2017/1/1. N2 - In cases of multiple lung cancers, individual tumors may represent either a primary lung cancer or both primary and metastatic lung cancers. Treatment selection varies depending on such features, and this discrimination is critically important in predicting prognosis. The present study was undertaken to determine the efficacy and validity of mutation analysis as a means of determining whether multiple lung cancers are primary or metastatic in nature. The study involved 12 patients who underwent surgery in our department for multiple lung cancers between July 2014 and March 2016. Tumor cells were ...
The Small Cell Lung Cancer Treatment Market is driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents. The market growth is estimated to occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan.. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Small Cell Lung Cancer Treatment Market ResearchReport at- http://www.absolutereports.com/opportunityanalyzer-small-cell-lung-cancer-sclc-opportunity-analysis-and-forecasts-to-2024-10112598. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor "Yervoy" will be the first immunotherapy to be introduced in the market. This drug is being developed by Bristol-Myers Squibb and will be launched in 2016 across the seven major markets.. The increase in rates of the disease across the five European markets and Japan, at a CAGR of 1.49% over the forecast period is estimated to further bolster the Small Cell Lung Cancer treatment ...
This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been shown to provide excellent results when used in early stage lung cancer, but has not yet been applied to patients with more advanced disease ...
Since 2000, the WHPP Early Lung Cancer Detection (ELCD) Program has provided low-dose chest CT scans to U.S. Department of Energy (DOE) workers, with the primary purpose of detecting lung cancers early. The WHPP ELCD Program serves DOE workers from nine sites in the DOE complex: Idaho National Laboratory (INL); the K-25, Paducah and Portsmouth gaseous diffusion plants (GDPs); the Mound and Fernald closure sites; the Nevada National Security Site (formerly the Nevada Test Site); Oak Ridge National Laboratory; and Y-12. As of September 2015, over 13,000 DOE workers have received low-dose screening CT scans through the ELCD Program; 136 lung cancers have been detected, with the majority (71%) found in early stages.. WHPP participants with an elevated risk of lung cancer based on age, smoking and work history are currently offered annual screening, as well as interim follow-up CT scans, if needed.. A low-dose screening CT scan of the chest uses much less radiation than a standard, full-dose CT scan ...
An increasing number of chromosomal aberrations is being identified in solid tumors providing novel biomarkers for various types of cancer and new insights into the mechanisms of carcinogenesis. We applied next generation sequencing technique to analyze the transcriptome of the non-small cell lung carcinoma (NSCLC) cell line H2228 and discovered a fusion transcript composed of multiple exons of ALK (anaplastic lymphoma receptor tyrosine kinase) and PTPN3 (protein tyrosine phosphatase, nonreceptor Type 3). Detailed analysis of the genomic structure revealed that a portion of genomic region encompassing Exons 10 and 11 of ALK has been translocated into the intronic region between Exons 2 and 3 of PTPN3. The key net result appears to be the null mutation of one allele of PTPN3, a gene with tumor suppressor activity. Consistently, ectopic expression of PTPN3 in NSCLC cell lines led to inhibition of colony formation. Our study confirms the utility of next generation sequencing as a tool for the ...
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have recently been described in patients with non-small-cell lung cancer (NSCLC) who achieve radiographic regressions to the EGFR inhibitor gefitinib. One of these mutations, L858R (Leu→Arg), is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment. We characterized nine NSCLC cell lines (three isolated from patients with bronchioloalveolar carcinoma and six isolated from patients with adenocarcinoma) for their in vitro sensitivity to gefitinib. Of these, only H3255 (EGFRL858R) and H1666 (EGFRWT) are sensitive to gefitinib with IC50 values of 40 nmol/L and 2 μmol/L, respectively. We examined the effects of gefitinib on H3255 and cell lines containing wild-type EGFR that are either sensitive (H1666) or resistant (A549 and H441) to gefitinib exposure in vitro. Gefitinib treatment (1 μmol/L) leads to significant apoptosis accompanied by increased poly(ADP-ribose) ...
[130 Pages Report] Check for Discount on United States Non Small Cell Lung Cancer Therapeutics Industry 2016 Market Research Report report by QYResearch Group. The United States Non Small Cell Lung Cancer Therapeutics Industry...
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early stage NSCLC. Several studies have reported high local control and survival using SBRT in stage I NSCLC patients. SBRT is now an accepted treatment for medically inoperable patients with stage I NSCLC and patients with operable stage I lung cancer are entered on clinical protocols. The purpose of this study is to conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current standard of care for stage I operable NSCLC ...
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Wright on life chances with non small cell lung cancer: Stage 1 nsclc; surgical resection, appr70%5yrsurv stage2nsclc;surgery apprx. 30-35% 5 yr survival. for topic: Life Chances With Non Small Cell Lung Cancer
Between 1990 and 2011, almost 720,000 people were diagnosed with lung cancer. During this time, the number of male lung cancer diagnoses declined, whereas the number of female lung cancer diagnoses increased. Lung cancer incidence increases sharply after middle age. More than 75% of lung cancers are diagnosed in people over the age of 65. The difference in the trends of lung cancer incidence among men and women is even more pronounced when age is taken into account. The sharp decrease in the incidence of male lung cancer over the past two decades reflects the decline in smoking prevalence among men. However, due to the rise in women who took up smoking after World War II, the incidence among women continues to increase. The difference in smoking prevalence between men and women has given rise to a dramatic change in the male to female lung cancer incidence ratio from 3:1 in 1990 to 3:2 in 2011.. ...
For patients with Stage III non-small cell lung cancer, prophylactic (preventive) radiation therapy to the brain reduces the risk of brain metastases but carries a risk of memory problems and doesnt appear to improve overall survival. These results were published in the Journal of Clinical Oncology.. Lung cancer remains the leading cause of cancer death in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.. One of the sites to which NSCLC can spread (metastasize) is the brain. Brain metastases can have a profound effect on survival and quality of life.. Prophylactic cranial irradiation (PCI) refers to the administration of radiation to the brain before brain metastases become apparent. The goal of PCI is the prevention of brain metastases. Previous studies have suggested that PCI can reduce the occurrence of brain metastases, but PCI has not become a part of routine NSCLC care because of concern about side effects and lack of evidence that ...
Objective: Lung cancer is the leading cause of cancer-related mortality worldwide. Disease stage still remains the best prognostic factor for patients with localized non-small cell lung cancer. The TNM staging system, however, does not address the heterogeneity of this disease. Sub-classification and identification of distinct prognostic sub-groups within each stage may allow the optimization of clinical trial design and potentially improve outcome. This is a retrospective pilot study, in which we attempt to identify genomic biomarkers predictive of recurrence in stage I lung cancer by analysing copy number (CN) data obtained by next-generation sequencing. Materials and Methods: Ninety eight patients with stage I NSCLC, who underwent elective radical surgery were identified from a tissue bank of 323 tumour samples. Their demographic and surgical data, including their recurrence status were collected and an extensive database compiled. The cases were split into two cohorts depending on their ...
TY - JOUR. T1 - Inactivation of LLC1 gene in nonsmall cell lung cancer. AU - Hong, Kyeong Man. AU - Yang, Sei Hoon. AU - Chowdhuri, Sinchita Roy. AU - Player, Audrey. AU - Hames, Megan. AU - Fukuoka, Junya. AU - Meerzaman, Daoud. AU - Dracheva, Tatiana. AU - Sun, Zhifu. AU - Yang, Ping. AU - Jen, Jin. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Serial analysis of gene expression studies led us to identify a previously unknown gene, c20orf85, that is present in the normal lung epithelium but absent or downregulated in most primary non-small cell lung cancers and lung cancer cell lines. We named this gene LLC1 for Low in Lung Cancer 1. LLC1 is located on chromosome 20q13.3 and has a 70% GC content in the promoter region. It has 4 exons and encodes a protein containing 137 amino acids. By in situ hybridization, we observed that LLC1 message is localized in normal lung bronchial epithelial cells but absent in 13 of 14 lung adenocarcinoma and 9 out of 10 lung squamous carcinoma samples. Methylation at CpG ...
... is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
... is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Disorders of cell adhesion are critical steps in cancer progression in which varieties of markers including cadherins are involved in.Btbd7 was found to inhibit E-cadherin expression in MDCK cells and play important roles during branching morphogenesis of embryonic salivary glands and lungs. However its function in malignant tumors is largely unknown. The aim of this study is to investigate the clinicopathological significance and possible function of Btbd7 in non-small cell lung cancer. Immunohistochemistry and Western blotting were used to investigate Btbd7 expression in non-small cell lung cancer and lung tissues. The clinicopathological association and the overall survival was analyzed. In vitro experiments were performed using siRNA to investigate the function of Btbd7 in lung cancer cells. Btbd7 expression was elevated in non-small cell lung cancer tissues compared to normal lung tissues. Increased Btbd7 expression was significantly associated with lymph node metastasis, reduced E-cadherin
... is very low. This kind of lung cancer can prolong life but only for minimal months. It is a stage that involves cancer
TY - JOUR. T1 - Comparison study of quality of life in advanced lung cancer patients on tyrosine kinase inhibitor and platinum doublet chemotherapy. AU - Udupa, K.. AU - Rajendranath, R.. AU - Sagar, T. G.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - INTRODUCTION: Lung cancer is most common cause of cancer death in the world. Most of the patient are diagnosed in the late stages and receive only palliative treatment. The main objective of the palliative chemotherapy is to improve survival as well as the quality of life (QOL). QOL is the most neglected dimension of cancer care in developing countries like India. Palliative chemotherapeutic agent which has minimum toxicity and prolongs the survival of metastatic cancer patients is the need of the day. MATERIALS AND METHODS: In this study, 43 metastatic adenocarcinoma of lung patients of South Indian origin were enrolled. Twenty patients out of this 43 were epidermal growth factor receptor (EGFR) mutation positive and were started on tyrosine kinase ...
Data & statistics on Lung cancer mortality by ethnic group age group and sex: Lung cancer mortality, by ethnic group, age group and sex, 2011, Lung Cancer Mortality Rates by Sex and Ethnicity 1987-1995 Age-adjusted lung cancer mortality rates by sex and ethnicity for the combined period 1990 through 1995, along with their 95% confidence intervals and the rate ratios of each group compared to White rates, are shown in Table 21. (See also Figures 6 and 7, pp. 28-29) Table 21: Lung Cancer Mortality Rates and Rate Ratios by Ethnicity and Sex, ..., That the lung cancer mortality rates in North Denver women were higher than rates in the remainder of the Metro area in all race/ethnicity groups; the differences were statistically significant for all races combined, and white non-Hispanics. For males, lung cancer mortality rates in North Denver were higher than other Metro area rates for all races combined, white non-Hispanics, and Hispanics, but ......
Lung cancer remains the major cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) account for at least 80% of all lung tumors and about 30% of them present with unresectable locally advanced disease at diagnosis (stage IIIA-IIIB) [1]. Until the mid 1980s standard treatment of patients with inoperable locally advanced NSCLC consisted of radiotherapy (RT) alone with a median survival time of 10 months[1]. From data about lung cancer population diagnosed in the second half of 1990s, overall survival at one and two years was estimated of 36% and 12% respectively[2].. Rates at 2 and 5 years of 15% and 5% respectively [3]. In attempts to improve the survival in these patients, chemotherapy was added to external beam irradiation. Several trials have been positive in favour of combined therapy [4-6]. More recently, other clinical trials have shown that, in selected patients (good performance status, age ≤ 75 years and minimal weight loss) concomitant platinum-based ...
Inactivation of the p16 and ESR1 tumor suppressor genes by promoter lesion methylation has been reported in many tumor types, including lung cancer. We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR. For both genes, there was a statistically significant difference in the methylation ratio between non-small cell lung cancer patients and controls (p16; ...
TY - JOUR. T1 - Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. AU - Improta, Giuseppina. AU - Zupa, Angela. AU - Natalicchio, Maria Iole. AU - Sisinni, Lorenza. AU - Marinaccio, Anna. AU - Bozza, Giovanni. AU - Vita, Giulia. AU - Aieta, Michele. AU - Landriscina, Matteo. PY - 2018/1/31. Y1 - 2018/1/31. N2 - Exons 19-21 EGFR activating mutations are predictive biomarkers of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, uncommon exon 19 EGFR mutations, due to their low frequency, have an uncertain biological and clinical significance and very little is known about their TKI sensitivity. This study was designed to describe the TKI sensitivity of a small cohort of lung adenocarcinomas bearing uncommon exon 19 mutations and to evaluate in silico the correlation between frame-shift exon 19 mutations and EGFR sequence/structure modification. Among 1168 NSCLCs screened for ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Survival of Patients with Stage I Lung Cancer Detected on CT Screening
Effects of interferons and tumour necrosis factor-a on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. ...
1. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893:1-19 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30 3. Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1-10 4. Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H. et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3. Oncogene. 2018;37:4300-12 5. Dragnev K, You M Fau - Wang Y, Wang Y Fau - Lubet R, Lubet R. Lung cancer chemoprevention: difficulties, promise and potential agents?. Expert Opin Investig Drugs. 2013;22:35-47 6. Li Q, Zhang D, Chen X, He L, Li T, Xu X. et al. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Scientific reports. 2015;5:16082 7. Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X. et al. Continuous ...
San Antonio (TX), Bolton (MA). As originally published in International Clinical Trials, May 2015 - View PDF. In the fight against non-small cell lung cancer, all eyes have been on computed tomography imaging to aid early detection. But advances in the field are leading the oncology and radiology communities to consider novel measurement parameters and techniques to better assess tumour response.. Lung Cancer: Lung cancer is the leading cause of cancer death across the globe, claiming more lives than the next three most common cancers combined (colon, breast and pancreatic). In 2012, the estimate for new cases of lung cancer reached 226,160, with 164,770 deaths accounting for 27% of all cancer deaths. The five-year survival rate is low at 16%, often due to most patients having advanced disease at the time of presentation.. Non-small cell lung cancer (NSCLC) accounts for some 85% of lung cancer diagnoses. Fortunately for this subset of patients, surgery can often be curative, but only if ...
peak seen in female lung cancer rates. Male lung cancer rates peaked in 1984 … can get lung cancer. In fact, about two thirds of lung cancer diagnoses are … of lung cancer: small cell lung cancer, and the more common non-small cell lung cancer (NSCLC … are dying of lung cancer, yet few women identify lung cancer as a serious ...
Screening lung cancer tumor samples for cancer-causing, or driver, genetic mutations can help physicians tailor patients treatments to target those specific mutations. While scientists have identified cancer-causing mutations ...
TY - JOUR. T1 - Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70. T2 - A multi-institutional case-control study. AU - Zimmermann, Matthias. AU - Nickl, Stefanie. AU - Lambers, Christopher. AU - Hacker, Stefan. AU - Mitterbauer, Andreas. AU - Hoetzenecker, Konrad. AU - Rozsas, Anita. AU - Ostoros, G.. AU - Laszlo, Viktoria. AU - Hofbauer, Helmut. AU - Renyi-Vamos, Ferenc. AU - Klepetko, Walter. AU - Döme, B.. AU - Ankersmit, Hendrik Jan. PY - 2012/7/11. Y1 - 2012/7/11. N2 - Introduction: Lung cancer represents a major healthcare problem. Accordingly, there is an urgent need to identify serum biomarkers for early diagnosis of lung pathology. We have recently described that patients with manifest COPD evidence elevated levels of heat shock proteins (HSPs). Based on these data, we speculated whether HSPs are also increased in patients with diagnosed lung cancer. Methods: Serum levels of HSP27, phospho-HSP27 (pHSP27) and HSP70 in patients with ...
A summary of the article is shown below:. MicroRNAs (miRNAs) function as key regulators of numerous types of cancers. miRNA (miR)‑421 expression is dysregulated in a variety of tumors; however, its role in non‑small cell lung cancer (NSCLC) remains unclear. In the present study, the role and molecular mechanism of miR‑421 in NSCLC was investigated. In this study, miRNA (miR)‑421 was upregulated in NSCLC tissues and cell lines used the reverse transcriptase quantitative polymerase chain reaction. Ectopic expression of miR‑421 significantly promoted cell proliferation in vitro and tumor growth in vivo by promoting cell cycle progression via CCK-8, colony formation, EdU assay, xenograft model and cell cycle assay. In addition, miR‑421 inhibited NSCLC cell apoptosis by flow cytometry apoptosis assay, as evidenced by anti‑apoptosis gene Bcl‑2 and apoptosis gene cleaved caspase‑3 and cleaved PARP using western blot assay. Furthermore, miR‑421 promoted cell migration and invasion ...
CUL4A has been proposed as oncogene in several types of human cancer, but its clinical significance and functional role in human non-small cell lung cancer (NSCLC) remain unclear. Expression level of CUL4A was examined by RT-PCR and Western blot. Forced expression of CUL4A was mediated by retroviruses, and CUL4A silencing by shRNAs expressing lentiviruses. Growth capacity of lung cancer cells was measured by MTT in vitro and tumorigenesis in vivo, respectively. We found that CUL4A was highly expressed in human lung cancer tissues and lung cancer cell lines, and this elevated expression positively correlated with disease progression and prognosis. Overexpression of CUL4A in human lung cancer cell lines increased cell proliferation, inhibited apoptosis, and subsequently conferred resistance to chemotherapy. On other hand, silencing CUL4A expression in NSCLC cells reduced proliferation, promoted apoptosis and resulted in tumor growth inhibition in cancer xenograft model. Mechanistically, we ...
Impact of maximum standardized uptake value of non-small cell lung cancer on detecting lymph node involvement in potential stereotactic body radiotherapy candidates
WASHINGTON - Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data from a phase I clincal trial presented here at the AACR Annual Meeting 2017, April 1-5.. According to the National Cancer Institutes SEER data, five-year survival rate for patients with advanced lung and bronchus cancer is 4.3 percent, and for those with advanced NSCLC, it is 4.9 percent.. "This is the first report of the long-term survival rate in patients with metastatic NSCLC treated with an immune checkpoint inhibitor. Our study results show that for a small subset of patients, immunotherapy can work for a very long time," said Julie Brahmer, MD, associate professor of oncology at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins.. "The five-year overall survival rate reported in this study is much higher than what is reported for this ...
Non-small cell lung cancer ( NSCLC ) is one of the most common types of lung cancer and accounts for up to 85% of diagnoses. Survival rates vary depending on the stage and type of the cancer when diagnosed. For patients diagnosed with metastatic lung cancer, the five-year survival rate is approximately 5%. ( Xagena ...
The purpose of this study is to understand real world outcomes in patients with non small cell lung cancer treated with Erlotinib or Afatinib.
Purpose: To evaluate planning quality of SBRT with multiple lung metastases generated with Pinnacle and Tomotherapy Methods: Nine randomly selected patients diagnosed with non small-cell lung cancer with multiple lesions were planned with Pinnacle (version 9.2) and Tomotherapy (version 4.2). Coplanar and non-coplanar plans were generated on Pinnacle. A total dose of 60 Gy was prescribed to 95% of PTV in 3 fractions. Single isocenter was used. Nine static beams were used for Pinnacle plans. Planning outcomes such as minimum and mean dose, V{sub 9} {sub 5}, D{sub 9} {sub 5} (95% of target volume receives prescription dose), D{sub 5}, and D{sub 1} to PTV, maximum dose to heart, esophagus, cord, trachea, brachial plexus, rib, chest wall, and liver, mean dose to liver, total lung, right and left lung, volume of chest wall receives 30 Gy, volume of lungs receives 5 Gy and 20Gy, conformity index (CI = PIV / PTV) and heterogeneity index (HI = D{sub 5} / D{sub 9} {sub 5}) were reported for evaluation. ...
Stage III non-small cell lung cancer (NSCLC) patients constitute a significant proportion of the lung cancer population. The prognosis of these patients
Lung Cancer Treatment of Alternative Lung Cancer Alternative Neuro Acupuncture Treatment and Lung Cancer Herbal Herbs Alternative Medicine Treatment on Lung Cancer Treatment Medical Center Lung Cancer Remedies
Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non-small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. See the image below.
Ras. Ras is an oncogene that is altered in up to 30% of non small cell lung cancers (NSCLC).17 The ras protein is involved in transmitting signals through the cell that drive the cell into the division process. Learn more about Ras. Myc. The Myc family of oncogenes that are expressed abnormally in many types of cancer, including lung cancer. The myc protein acts as a transcription factor to regulate the expression of several genes. Learn more about transcription and transcription factors. Myc protein expression is altered in up to 80% of small cell lung cancers (SCLC).17Learn more about Myc. Rb. The retinoblastoma gene (Rb) is a tumor suppressor altered in up to 90% of small cell lung cancers (SCLC).17Learn more about tumor suppressors The Rb protein interacts with transcription factors to indirectly control cell division. Learn more about Rb. TP53. TP53 (or P53) is a tumor suppressor gene altered in up to 50% of non small cell lung cancers (NSCLC) and 80% of small cell lung cancers (SCLC).17 ...
The use of radiofrequency ablation for the treatment of lung cancer and lung metastases from breast, colon, and prostate cancers and melanoma is effective and safe for some patients. These results were recently published in the Lancet Oncology.. Lung cancer is responsible for more cancer-related deaths than the next three most deadly cancers combined. If cancer originates in the lung, it is referred to as primary lung cancer. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer; "non-small cell" refers to the type of cell within the lung where the cancer originated.. Lung metastasis refers to cancer that has spread to the lung from other sites in the body. Lung metastases are common among patients diagnosed with advanced breast, colon, and prostate cancers as well as melanoma and other solid tumors.. Treatment for primary lung cancer and lung metastases often consists of the surgical removal of the cancer, radiation therapy, targeted therapy, chemotherapy, and hormone ...
Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.
The clinical significance of CXCL5 in non-small cell lung cancer Kongju Wu,1,* Shengnan Yu,2,* Qian Liu,2 Xianguang Bai,1 Xinhua Zheng,1 Kongming Wu2 1Medical School of Pingdingshan University, Pingdingshan, Henan, 2Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, Peopleâ s Republic of China *These authors contributed equally to this work Abstract: As a CXC-type chemokine, ENA78/CXCL5 is an important attractant for granulocytes by binding to its receptor CXCR2. Recent studies proved that CXCL5/CXCR2 axis plays an oncogenic role in many human cancers. However, the exact clinical significance of CXCL5 in lung cancer has not been well defined. Here, we found that the serum protein expression of CXCL5 was significantly increased in non-small cell lung cancer (NSCLC) compared with that in healthy volunteers. Immunohistochemistry staining revealed that CXCL5 protein was higher in various lung cancer tissues compared with
TY - JOUR. T1 - Determinants of drug response in a cisplatin-resistant human lung cancer cell line. AU - Fujiwara, Yasuhiro. AU - Sugimoto, Yoshikazu. AU - Kasahara, Kazuo. AU - Bungo, Masami. AU - Yamakido, Michio. AU - Tew, Kenneth D.. AU - Saijo, Nagahiro. PY - 1990/5. Y1 - 1990/5. N2 - To elucidate the mechanism(s) of cisplatin resistance, we have characterized a human non-small cell lung cancer cell line ( PC-9 CDDP) selected from the wild type (PC-9) for acquired resistance to cisplatin. PC-9 CDDP demonstrated 28-fold resistance to cisplatin, with cross resistance to other chemotherapeutic drugs including chlorambucil (×6.3), melphalan (×3.7) and 3-[(4-amino-2-methyl-5-pyrimidinyl)]methyl-1-(2-chloroethyl)-1-nitrosourea (ACNU) (×3.9). There was no expression of mdr-1 mRNA in either wild-type or resistant cells. The mRNA and protein levels of glutathione S-transferase (GST) π were similar in the two lines. A GST-μ isozyme was present in equal amounts and the activities of ...
Chapter 107: Neoplasms of the lung. (编) Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison's Principles ... 非小細胞癌(NSCLC)可粗分為三大類:肺腺癌、鱗狀上皮癌(英语:squamous-cell lung carcinoma),和大細胞癌(英语:large-cell lung carcinoma)[1]。 ... 肺癌(英語:Lung cancer[7])是惡性的肺部肿瘤,肇因於肺部組織细胞不受控制地生長(英语:cell growth)[10]。如不治疗,肿瘤细胞會转移至鄰
These were cancers of the brain, lung, bowel, breast, and bladder, and other neoplasms. Not only are benzodiazepines associated ...
"Lung atelectasis". Radiopaedia. Retrieved 20 February 2017.. *^ "Lung folding simulating peripheral pulmonary neoplasm ( ... In rounded atelectasis (Folded lung or Blesovsky syndrome[10]), an outer portion of the lung slowly collapses as a result of ... findings can include lung opacification and/or loss of lung volume. Post-surgical atelectasis will be bibasal in pattern. Chest ... It may affect part or all of a lung.[1] It is usually unilateral. It is a condition where the alveoli are deflated down to ...
A number of disorders have been mapped in the vicinity of this gene, most notably lung neoplasms. GRCh38: Ensembl release 89: ...
The cancers included cancer of the brain, lung, bowel, breast, and bladder, and other neoplasms. It has been hypothesised that ... A recent case-control study, however, found no link between use of benzodiazepines and cancers of the breast, lung, large bowel ... June 1995). "Relation of Benzodiazepine Use to the Risk of Selected Cancers: Breast, Large Bowel, Malignant Melanoma, Lung, ... lung, uterine lining, ovaries, testes, thyroid, liver, or Hodgkin's Disease, melanoma, or non-Hodgkin's lymphoma. More specific ...
Tobacco smoke causes increased exogenous DNA damage, and these DNA damages are the likely cause of lung cancer due to smoking.[ ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term 'neoplasm' is a synonym of "tumor". 'Neoplasia' denotes the process of the formation of neoplasms/tumors, the process ... "II Neoplasms". World Health Organization. Retrieved 19 June 2014.. *^ a b Abrams, Gerald. "Neoplasia I". Retrieved 23 January ...
A study of 93 patients with incurable neoplasms". J Natl Med Assoc. 43 (4): 211-240. PMC 2616951. PMID 14850976.. ... It is effective for the treatment of a number of cancers, including: breast, head and neck, leukemia, lymphoma, lung, ... lung disease, lymphoma, and severe skin rashes.[1] People on long-term treatment should be regularly checked for side effects.[ ... lung cancer, lymphoma, and osteosarcoma.[1] Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis ...
A study of 93 patients with incurable neoplasms". J Natl Med Assoc. 43 (4): 211-240. PMC 2616951 . PMID 14850976. Li, MC; Li, R ... Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, and osteosarcoma. Types of autoimmune ... Other side effects may include liver disease, lung disease, lymphoma, and severe skin rashes. People on long-term treatment ... It is effective for the treatment of a number of cancers, including: breast, head and neck, leukemia, lymphoma, lung, ...
Horn, L; Lovly, CM; Johnson, DH (2015). "Chapter 107: Neoplasms of the lung". In Kasper, DL; Hauser, SL; Jameson, JL; Fauci, AS ... Lung cancer, also known as lung carcinoma,[7] is a malignant lung tumor characterized by uncontrolled cell growth in tissues of ... This article is about lung carcinomas. For other lung tumors, see Lung tumor. ... Most cancers that start in the lung, known as primary lung cancers, are carcinomas.[12] The two main types are small-cell lung ...
Necrotizing tumors: 8% to 18% are due to neoplasms across all age groups, higher in older people; primary squamous carcinoma of ... Lung abscess is a type of liquefactive necrosis of the lung tissue and formation of cavities (more than 2 cm)[1] containing ... Lung abscess is considered primary (60%[2]) when it results from existing lung parenchymal process and is termed secondary when ... Lower RT/lung disease. (including LRTIs). Bronchial/. obstructive. acute. Acute bronchitis. chronic. COPD Chronic bronchitis. ...
... lung, pancreas, and colon neoplasms. PELP1 signaling contributes to hormonal therapy resistance. Altered localization of PLP1 ... AR, PELP1 and Src form constitutive complexes in prostate neoplasms model cells that exhibit androgen independence. Cytoplasmic ... and leucine-rich protein PELP1 in non-small cell lung cancer". Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie. ...
... most commonly reticular neoplasms, lung tumours, and renal tumours. Most substrains have a "long reproductive life-span", are ...
Large cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed ... Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ... Lung adenocarcinoma[edit]. Main article: Adenocarcinoma of the lung. Adenocarcinoma of the lung is currently the most common ... Historically, adenocarcinoma was more often seen peripherally in the lungs than small cell lung cancer and squamous cell lung ...
... and other neoplasms (e.g., lung cancer, lymphoma, and leukemia). Diet may also modulate risk. For example, among immigrants in ... chronic lung disease, malnutrition, and alcoholism. A person's genetics also play a role. People with silicosis have an ...
Cancer (including neoplasms in the mammalian lung, oral/nasal cavities, thyroid and adrenal glands, and liver, squamous cell ...
... and lung neoplasms. A small amount of the rat population was able to clear particulate curium sesquioxide from the lungs, ... "Dose Responses from Inhaled Monodisperse Aerosols of 244Cm203 in the Lung, Liver and Skeleton of F344 Rats and Comparison with ... suggesting that curium sesquioxide is partially soluble in lung fluid. Curium(III) oxide is heavily used in industrial grade- ...
... lung cancer, pediatric neoplasms, stereotactic radiosurgery, radiosensitization, combined modality therapies, altered ... He has run numerous multimodality clinical trials at the national level for both adult and pediatric CNS neoplasms. Current ... Combined modality treatment of tumors of the CNS and thorax, as well as pediatric neoplasms: integrating systemic chemotherapy ...
Spivach A, Borea B, Bertoli G, Daris G (July 1976). "[Primary lung neoplasm of rare incidence: giant cell carcinoma]". Minerva ... The new paradigm recognizes that lung cancers are a large and extremely heterogeneous family of malignant neoplasms, with over ... Travis WD (November 2010). "Sarcomatoid neoplasms of the lung and pleura". Arch. Pathol. Lab. Med. 134 (11): 1645-58. doi: ... About 1% of lung cancers are sarcomas, germ cell tumors, and hematopoietic tumors, while 99% of lung cancers are carcinoma. ...
... mental retardation Thymic carcinoma Thymic epithelial tumor Thymic renal anal lung dysplasia Thymoma Thymus neoplasm ... Temtamy-Shalash syndrome TEN Ter Haar-Hamel-Hendricks syndrome Ter Haar syndrome Teratocarcinosarcoma Teratoma Testes neoplasm ... syndrome Tolosa-Hunt syndrome Toluene antenatal infection Tomaculous neuropathy Tome-Brune-Fardeau syndrome Tongue neoplasm ... Trisomy 14 mosaicism Trisomy 2 mosaicism Trisomy 3 mosaicism Trisomy 6 Trisomy Trochlear dysplasia Trophoblastic Neoplasms ( ...
... syndrome Lung agenesis heart defect thumb anomalies Lung cancer Lung herniation congenital defect of sternem Lung neoplasm ... Labrador lung Labyrinthitis Lachiewicz-Sibley syndrome Lacrimo-auriculo-dento-digital syndrome Lactate dehydrogenase deficiency ... Lymph node neoplasm Lymphadenopathy, angioimmunoblastic with dysproteinemia Lymphangiectasies lymphoedema type Hennekam type ... isolated Lissencephaly Listeria infection Listeriosis Livedoid dermatitis Liver cirrhosis Liver neoplasms Lobar atrophy of ...
... lung adenocarcinoma, lung squamous cell carcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, pancreatic adenocarcinoma, ...
... in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue. Lung cancer is an ... curing lung cancer, (2) controlling lung cancer, and (3) being comfortable. In most cases, the goal of lung cancer surgery is ... "Lung-Sparing Surgery Effective for Early-Stage Lung Cancer". Medscape Medical News. Gale, Karla (2 November 2010). "Lung Cancer ... Surgery is very rarely used in cases of stage 3b or stage 4 non-small cell lung carcinoma. In patients with stage 3 lung cancer ...
Approximately 99% of lung cancers are carcinoma, a term that indicates that the malignant neoplasm is composed of, or descended ... Combined small cell lung carcinoma (or c-SCLC, and rarely rendered as "small-cell lung carcinoma") is a form of multiphasic ... April 2008). "Genetic alterations in combined neuroendocrine neoplasms of the lung". Mod. Pathol. 21 (4): 414-22. doi:10.1038/ ... Lung Cancer Home Page. The National Cancer Institute site containing further reading and resources about lung cancer. [1]. ...
Maleki Z (March 2011). "Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid ... Lung cancer is a large and exceptionally heterogeneous family of malignancies. Over 50 different histological variants of lung ... Basaloid carcinomas of the lung - like nearly all recognized variants of lung cancer - are highly associated with tobacco ... The true incidence and prevalence of basaloid squamous cell lung carcinoma remains unknown, but this form of lung cancer is ...
... bronchus or lung (C34.3) Lower lobe, bronchus or lung (C34.8) Overlapping lesion of bronchus and lung (C37) Malignant neoplasm ... Malignant neoplasm of larynx (C33) Malignant neoplasm of trachea (C34) Malignant neoplasm of bronchus and lung (C34.0) Main ... Neoplasms. (C00) Malignant neoplasm of lip (C01) Malignant neoplasm of base of tongue (C02) Malignant neoplasm of other and ... Malignant neoplasm of breast (C51) Malignant neoplasm of vulva (C52) Malignant neoplasm of vagina (C53) Malignant neoplasm of ...
... neoplasms including sarcomas such as hemangiopericytoma and malignant peripheral nerve sheath tumor in ... Allow organs like arteries and lungs to recoil. Elastic microfibril and elastin. extracellular matrix ...
Lung NeoplasmsA Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung ... Lung NeoplasmsA Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung ... Lung NeoplasmsValidation of Molecular Diagnostic Thecnologies for Lung Cancer Patients. NCT03220230. * Fortaleza, Caera ... Lung NeoplasmsA Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy ...
Anatomical context of Lung Neoplasms. *The doxorubicin-selected lung cancer cell line H69AR is resistant to many ... Chemical compound and disease context of Lung Neoplasms. *Treatment of non-small-cell lung cancer with cisplatin and ... High impact information on Lung Neoplasms. *Somatic activating mutations in EGFR identify a subset of non-small cell lung ... Gene context of Lung Neoplasms. *The FHIT gene 3p14.2 is abnormal in lung cancer [34]. ...
Non-small Cell Lung Carcinoma Cancer trial. Review trial description, criteria and location information here. ... Pfizer is currently recruiting for the NCT00094094 Lung Neoplasms, ...
Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non-Smoking Women in China. *Lung Neoplasms ... Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China. *Lung Neoplasms ... TF2- Small Cell Lung Cancer Radio Immunotherapy. *Small Cell Lung Cancer. *CEA-expressing Non Small Cell Lung Carcinoma (NSCLC) ... National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria. *Oncology & Epidemiology & Lung Cancer ...
Feasibility Study Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients. *Lung Neoplasms ... Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency. *Lung Neoplasms ... Circulating Tumor DNA in Surgical Lung Cancer Patients. *Lung Neoplasms. Observational. *Shenzhen Gene Health Bio Tech Co., Ltd ... A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer. *Lung Neoplasms ...
"Lung Neoplasms" by people in Harvard Catalyst Profiles by year, and whether "Lung Neoplasms" was a major or minor topic of ... "Lung Neoplasms" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Below are the most recent publications written about "Lung Neoplasms" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Lung Neoplasms". ...
... and malignancy of the lung neoplasm. In most cases... ... The treatment for a lung neoplasm varies depending on the cause ... Perhaps the most important of these is whether the tumor is a benign lung neoplasm or a malignant lung neoplasm. The doctor ... Most often, a lung neoplasm will turn out to be cancerous rather than benign, as around a third of lumps found in the lungs are ... A benign lung neoplasm is much rarer than a cancerous one, and benign neoplasms account for up to five percent of cases where a ...
... resected which developed after segmentectomy of a squamous cell carcinoma of the lung and radiologically mimicked a neoplasm. ...
Lung neoplasms explanation free. What is Lung neoplasms? Meaning of Lung neoplasms medical term. What does Lung neoplasms mean? ... Looking for online definition of Lung neoplasms in the Medical Dictionary? ... lung cancer. (redirected from Lung neoplasms). Also found in: Dictionary, Thesaurus, Encyclopedia. lung. [lung] either of two ... brown lung byssinosis.. lung cancer malignant growths of the lung. Although the exact cause of lung cancer is not known, ...
Lung - pathology Lung Neoplasms - epidemiology - etiology - pathology Middle Aged Mining Occupational Diseases - epidemiology ... In order to prevent such a late diagnostics all the miners should be referred to the group of risk on lung cancer. ... Clinical and morphologic characteristics of lung cancer in miners of Krivoy Rog iron-ore region and of uranium mines of Zhovti ... In all the cases lung cancer was morphologically proved and classified as squamous. Rapid progression of the disease and late ...
... many pa-tients diagnosed with primary lung cancer will not be surgical candidates. Percutaneous image-guided ... ... Although lung cancer has a high mortality rate, ... especially in the lung. A study in the porcine lung showed ... Current and future applications of percutaneous radiofrequency ablation in the treatment of lung neoplasms. By Michael D. ... Current and future applications of percutaneous radiofrequency ablation in the treatment of lung neoplasms. Appl Radiol. ...
HEPATIC NEOPLASM , Lung Neoplasm , Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors ...
Gastrointestinal Neoplasm , Bronchial Neoplasm , Lung Cancer , Breast Cancer , Bridge: Proactive Psychiatry Consultation and ... Lung Neoplasm , Bipolar Disorder , head and neck cancer , Schizophrenia , Severe Major Depression , ...
These can occur in the lung (1-5% of all lung tumours). Neuroendocrine neoplasm of low malignant potential - most bronchial ... 1. Small cell lung cancer (SCLC) (13%). 2. Non-small cell lung cancer (NSCLC). - SCC (20%). - Adenocarcinoma (40%). - Large ... In lung cancer this is because of the path over the apex of the lung ... and are most commonly found around the hilium of the lung (ex. adenocarcinoma). Regardless of subtype, all lung cancers tend to ...
Home > 2015 ICD-9-CM Diagnosis Codes > Neoplasms 140-239 > Benign Neoplasms 210-229 > Benign neoplasm of respiratory and ... 2015/16 ICD-10-CM D14.30 Benign neoplasm of unspecified bronchus and lung ...
Malignant Neoplasm Of Respiratory And Intrathoracic Organs 160-165 > Malignant neoplasm of trachea bronchus and lung 162- ... T4: Lung tumor of any size with a malignant pleural effusion. *T4: Lung tumor of any size with separate tumor nodule in same ... 2015/16 ICD-10-CM C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung ... Squamous cell carcinoma, right lung. *T3: Lung tumor of any size in the main bronchus < 2 cm distal to the carina but without ...
Erlotinib Active Not Recruiting Phase 1 Trials for Colon Neoplasms / Lung Cancers / Neoplasms, Breast / Malignant Neoplasm of ...
KEY WORDS: medicinal mushrooms, Agaricus brasiliensis, carcinogenesis tests, drug therapy, inflammation, neoplasms, lung ... NNK treatment induced pulmonary inflammation, but not lung cancer, in the rats. The lungs of animals treated with NNK showed a ... The effects of orally administered aqueous A. brasiliensis extract (14.3- and 42.9-mg doses) on parenchymal lung damage induced ...
Lung Diseases, Obstructive Subject Neoplasms Remove constraint Subject: Neoplasms ... You searched for: Genre Official reports Remove constraint Genre: Official reports Subject Lung Diseases, Obstructive Remove ... 6. The Health Consequences of Smoking: Cancer and Chronic Lung Disease in the Workplace: A Report of the Surgeon General ...
C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung C34.11 Malignant neoplasm of upper lobe, right bronchus ... C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung C34.31 Malignant neoplasm of lower lobe, right bronchus ... C34.32 Malignant neoplasm of lower lobe, left bronchus or lung C34.8 Malignant neoplasm of overlapping sites of bronchus and ... C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung C34.82 Malignant neoplasm of overlapping sites of ...
C34.91 Malignant neoplasm of unspecified part of right bronchus or lung C34.92 Malignant neoplasm of unspecified part of left ... Malignant neoplasm of bronchus and lung. 2016 2017 2018 Non-Billable/Non-Specific Code Type 1 Excludes*Kaposis sarcoma of lung ... C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung C34.31 Malignant neoplasm of lower lobe, right bronchus ... C34.32 Malignant neoplasm of lower lobe, left bronchus or lung C34.8 Malignant neoplasm of overlapping sites of bronchus and ...
... and metastatic lung malignancies. One hundred cases representing different types of neoplasms involving the anterior ... CK5/6 was a sensitive but not a specific IHC marker for the epithelial component of thymic neoplasms (100%); TTF-1 had a good ... An IHC panel consisting of CD5, CK5/6, PLAP, TTF-1, and CD57 is useful for the separation of thymic neoplasms from other ... and CD57 for the separation of thymic neoplasms from germ cell tumors (GCTs) ...
... apart from malignant neoplasms of the lung, it may also be of use in a large number of pathological conditions of the lung. We ... can be made today from chest radiograms or CT scan of the chest in a significant number of cases of secondary lung neoplasm. ... information on small improvements or deteriorations in the great majority of patients with malignant neoplasms of the lung ... The evaluation of low-intensity reduction in the compliance of the lung parenchyma (LIRCLP) can, we believe, give early ...
Extrapulmonary neoplasms in lung cancer screening. In: Translational Lung Cancer Research. 2018 ; Vol. 7, No. 3. pp. 368-375 ... Extrapulmonary neoplasms in lung cancer screening. Translational Lung Cancer Research. 2018 Jun 1;7(3):368-375. Available from ... title = "Extrapulmonary neoplasms in lung cancer screening",. abstract = "A significant reduction in lung cancer specific ... Extrapulmonary neoplasms in lung cancer screening Translational Lung Cancer Research, vol. 7, no. 3, pp. 368-375. DOI: ...
While lung cancer is the most common cause of malignant lesions in the lungs, many other malignant and benign lung neoplasms ... Beware: there are other diseases that can mimic lung neoplasms:*How and/or why did the patient develop a lung neoplasm?*Which ... Beware: there are other diseases that can mimic lung neoplasms:. Granulomatous lung diseases are the most common mimickers of ... Other Lung Neoplasms (including benign lung tumors, inflammatory pseudotumor/plasma cell granuloma, neuroendocrine tumors, ...
  • Investigate predictive models for long-term tumor control and late treatment lung toxicity by using FDG-PET-CT, V/Q SPECT-CT and blood test during the course of radiation therapy. (clinicaltrials.gov)
  • Perhaps the most important of these is whether the tumor is a benign lung neoplasm or a malignant lung neoplasm. (wisegeek.com)
  • Where there is any doubt about a tumor being benign, lung surgery is usually carried out to remove the lump. (wisegeek.com)
  • CONCLUSIONS: Tumor-infiltrating lymphocytes are observed in about one fourth of resected lung neoplasms: they are rare in neuroendocrine tumors. (unito.it)
  • Gastrointestinal stromal tumor masquerading as a lung neoplasm. (biomedcentral.com)
  • Purpose: Accurately localizing lung tumor localization is essential for high-precision radiation therapy techniques such as stereotactic body radiation therapy (SBRT). (osti.gov)
  • Since direct monitoring of tumor motion is not always achievable due to the limitation of imaging modalities for treatment guidance, placement of fiducial markers on the patient's body surface to act as a surrogate for tumor position prediction is a practical alternative for tracking lung tumor motion during SBRT treatments. (osti.gov)
  • Conclusions: The PCA model is an accurate, efficient, robust, and practical model for solving the multimarker position optimization problem to predict lung tumor motion during SBRT treatments. (osti.gov)
  • Quantitative MR diffusion imaging provides delineation of viable lung tumor and exhibits excellent correspondence with PET imaging. (ismrm.org)
  • Aside from the great heterogeneity seen in lung cancers (especially those occurring among tobacco smokers), the considerable variability in diagnostic and sampling techniques used in medical practice, the high relative proportion of individuals with suspected GCCL who do not undergo complete surgical resection, and the near-universal lack of complete sectioning and pathological examination of resected tumor specimens prevent high levels of quantitative accuracy. (wikipedia.org)
  • As a result, it is recommended that all multiphasic malignant lung tumors (i.e. those with more than one histological pattern) that are found to contain any proportion of SCLC cells should be classified as c-SCLC, and not as combined forms of any of the other histological variants present in the tumor. (wikipedia.org)
  • In right middle lobe syndrome, the middle lobe of the right lung contracts, usually because of pressure on the bronchus from enlarged lymph glands and occasionally a tumor. (wikipedia.org)
  • As well as tumors , lumps in the lungs may be caused by infections such as tuberculosis, cysts and abscesses. (wisegeek.com)
  • For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned. (icd10data.com)
  • We report an immunohistochemical (IHC) panel that includes CD5, placental-like alkaline phosphatase (PLAP), thyroid transcription factor 1 (TTF-1), cytokeratin (CK) 7, CK20, CK5/6, and CD57 for the separation of thymic neoplasms from germ cell tumors (GCTs) and metastatic lung malignancies. (semanticscholar.org)
  • Bronchial carcinoid tumors account for 2% to 5% of all lung malignancies and 20% of all carcinoid tumors. (pulmonologyadvisor.com)
  • This case serves as a review that not all lung tumors cause weight loss and night sweats, especially if the tumors are benign, and that lung tumors can also result in endobronchial obstruction and infection. (jaoa.org)
  • Causes of inflammatory lung diseases include smoking, asbestos, and air pollution and irritants, according to the Office of Women's Health. (reference.com)
  • Moreover, the case studies on lung neoplasms and prostate neoplasms also illustrate that BRWHNHA is superior to previous prediction methods and is more advantageous in exploring potential miRNAs related diseases. (nature.com)
  • Latero-lateral and ventral-dorsal radiographic images of thorax were done for identification of radiographic lesions suggestive of lung metastasis. (unicordoba.edu.co)
  • This study was designed to determine whether fenofibrate, a PPARα agonist, can suppress 4-nitroquinoline 1-oxide (4-NQO)-induced proliferative lesions in the lung of obese hyperlipidemic mice. (mdpi.com)
  • Male Tsumura Suzuki Obese Diabetic mice were subcutaneously injected with 4-NQO to induce lung proliferative lesions, including adenocarcinomas. (mdpi.com)
  • Our results indicate that fenofibrate can prevent the development of 4-NQO-induced proliferative lesions in the lung by modulating the insulin-IGF axis. (mdpi.com)
  • Maleki Z. Diagnostic issues with cytopathologic interpretation of lung neoplasms displaying high-grade basaloid or neuroendocrine morphology. (hopkinsmedicine.org)
  • Emphysema, COPD and chronic bronchitis cause scarring of the lung tissue, which is permanent. (reference.com)